1. Introduction

Pritha Dasgupta
Ph.D., Cancer Biology

2. Current research interest

  • Monitoring minimal residual disease (MRD) by PCR based on specific Ig/TCR rearrangement identification in childhood ALL patients
  •  Establishing NGS based MRD monitoring and standardizing the workflow for Illumina and Nanopore platforms.
  •  Developing different vectors to facilitate transient/stable cell-line generation to help understanding ALL biology

3. Research expertise

  • Molecular and cell biology techniques like cloning, protein expression and purification, PCR, SDS PAGE, Native PAGE, western blotting, immunofluorescence
  • MicroRNA expression analysis by real time PCR and in situ hybridization
  • DNA Methylation analysis by bisulfite method and methylation-specific PCR
  • Radiolabelling oligonucleotide, in vitro binding assay and electrophoretic mobility shift assays, immunoprecipitation assays
  •  Primary cultures and cell line maintenance (both adherent and suspension)
  • Transfection and transduction in cell lines, generation of stable cell lines (using crispr techniques)
  •  DNA, RNA, microRNA isolation from fresh, frozen or FFPE tissues and cell lines
  •  Generation of lentivirus and lentiviral infections in mammalian cells
  •  siRNAs, shRNAs and RNAi experiments in mammalian cells
  •  Reporter assays such as luciferase, -gal assays
  •  In vivo experimental expertise: Development of cancer models by subcutaneous, orthotopic, and intracardiac implantations in mouse, in-vivo live animal imaging by luminescence, fluorescence

4. Previous work experience

  • Postdoctoral Fellow: University of California San Francisco Medical School (Jan 2016 – Jan 2021) Studying the roles of non-coding RNAs and identifying biomarkers for kidney and prostate cancers
  • PhD student: University of Calcutta (March 2008 – May 2014) Studying anti-proliferative effects and mechanism of action of diallyl disulfides in human leukemic cell-lines


Pubmed link: https://pubmed.ncbi.nlm.nih.gov/?term=pritha+dasgupta

  1. P Kulkarni*, P Dasgupta*, Y Hashimoto, M Shiina, V Shahryari, L Tabatabai, S Yamamura, Y Tanaka, S Saini, R Dahiya, S Majid, “lncRNA TCL6-1 miRNA-155 interaction in the regulation of Src-Akt-EMT network mediated kidney cancer progression and metastasis” Cancer Research, 2021 (*equal contribution) Pubmed
  1. P Dasgupta*, P Kulkarni*, S Majid, Y Hashimoto, M Shiina, N S. Bhat, V Shahryari, L Tabatabai, S Yamamura, Y Tanaka, S Saini, R Dahiya, “LncRNA CDKN2B-AS1/ miR-141/ cyclin D network regulates tumor progression and metastasis of renal cell carcinoma” Cell Death & Disease, 2020 (*equal contribution) PubMed
  1. P Dasgupta*, P Kulkarni*, N S Bhat*, S Majid, M Shiina, V Shahryari, S Yamamura, Y Tanaka, R Kumar, R Dahiya, Y Hashimoto, “Activation of the Erk/MAPK signaling pathway is a driver for cadmium induced prostate cancer” Toxicology and Applied Pharmacology, 2020 (*equal contribution) PubMed
  1. M Imai-Sumida, P Dasgupta, P Kulkarni, M Shiina, Y Hashimoto, V Shahryari, S Majid, Y Tanaka, R Dahiya, S Yamamura, “Genistein represses HOTAIR/chromatin remodeling pathways to suppress kidney cancer” Cellular Physiology and Biochemistry, 2020 PubMed
  1. P Kulkarni , P Dasgupta , N S. Bhat , V Shahryari , M Shiina , Y Hashimoto , S Majid , G Deng , S Saini, Z. L Tabatabai , S Yamamura ,Y Tanaka, R Dahiya, “Elevated miR-182-5p Associates with Renal Cancer Cell Mitotic Arrest through Diminished MALAT-1 Expression” Molecular Cancer Research, 2018 PubMed
  1. P Dasgupta, P Kulkarni, S Majid, V Shahryari, Y Hashimoto, N S Bhat, M Shiina, G Deng, S Saini, S Yamamura, Y Tanaka, R Dahiya,“MicroRNA-203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma” Molecular Cancer Therapeutics, 2018 PubMed